The Pharmaceutical Industry has been an important driver of the global economy and advances in healthcare provision. In recent years there has been a critical review of costs, in the drug development process, that has seen a large shift in the provision of Clinical Trials data from pharmaceutical companies to Contract Research Organisations (CROs). Since the divestment of Clinical Diagnostic provision by the Pharmaceutical Industry, there is a gap in knowledge and expertise for immunoassay development in many pharmaceutical companies and CROs.
TopCat can provide that knowledge and expertise, with the added provision to develop products that may have a more commercial deployment. With our Stakeholder network, TopCat can develop and manufacture biomarker assays. This function can be carried out for both established and novel biomarkers.